KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Develops, manufactures, and markets OTC pharmaceuticals, health, and household goods.

4967 | T

Overview

Corporate Details

ISIN(s):
JP3301100008
LEI:
Country:
Japan
Address:
大阪市中央区道修町4丁目4番10号

Description

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:30
確認書
Japanese 8.1 KB
2025-08-08 08:30
半期報告書-第108期(2025/01/01-2025/12/31)
Japanese 226.4 KB
2025-03-31 08:27
臨時報告書
Japanese 25.4 KB
2025-03-28 07:33
確認書
Japanese 8.2 KB
2025-03-28 07:32
内部統制報告書-第107期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-28 07:32
有価証券報告書-第107期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-20 08:51
臨時報告書
Japanese 25.1 KB
2025-02-10 07:32
訂正臨時報告書
Japanese 24.5 KB
2025-01-21 09:01
臨時報告書
Japanese 20.7 KB
2024-12-26 05:03
臨時報告書
Japanese 20.5 KB
2024-11-08 07:41
訂正臨時報告書
Japanese 24.1 KB
2024-08-09 08:00
確認書
Japanese 8.1 KB
2024-08-09 08:00
半期報告書-第107期(2024/01/01-2024/12/31)
Japanese 240.4 KB
2024-08-08 08:30
訂正臨時報告書
Japanese 24.0 KB
2024-07-23 08:29
臨時報告書
Japanese 20.9 KB

Automate Your Workflow. Get a real-time feed of all KOBAYASHI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOBAYASHI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOBAYASHI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.